2.625

1.72% -0.045

Abcellera Biologics Inc (ABCL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ABCL Giù? Forum Previsione

Precedente Chiudi:

$2.67

Aprire:

$2.66

Volume 24 ore:

319.44K

Relative Volume:

0.15

Capitalizzazione di mercato:

$788.63M

Reddito:

$38.03M

Utile/perdita netta:

$-146.40M

Rapporto P/E:

-5.8333

EPS:

-0.45

Flusso di cassa netto:

$-121.38M

1 W Prestazione:

-4.93%

1M Prestazione:

-5.27%

6M Prestazione:

-31.84%

1 anno Prestazione:

-39.54%

Intervallo 1D:

$2.61

$2.7075

Intervallo di 1 settimana:

$2.57

$2.76

Portata 52W:

$2.335

$6.055

Abcellera Biologics Inc Stock (ABCL) Company Profile

Nome

Abcellera Biologics Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

(604) 559-9005

Indirizzo

2215 YUKON STREET, VANCOUVER

Dipendente

586

Cinguettio

Prossima data di guadagno

2024-11-18

Ultimi documenti SEC

ABCL's Discussions on Twitter

Confronta ABCL con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ABCL	2.625	788.63M	38.03M	-146.40M	-121.38M	-0.45
VRTX	445.82	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.34	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.04	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.89	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.89	24.49B	3.30B	-501.07M	1.03B	11.54

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-20	Downgrade	The Benchmark Company	Buy → Hold
2024-02-22	Aggiornamento	The Benchmark Company	Hold → Buy
2023-12-05	Iniziato	KeyBanc Capital Markets	Overweight
2023-11-06	Downgrade	The Benchmark Company	Buy → Hold
2023-10-13	Ripresa	Piper Sandler	Overweight
2023-02-28	Iniziato	Cowen	Outperform
2022-12-15	Iniziato	Goldman	Buy
2022-11-16	Iniziato	Truist	Buy
2021-12-21	Iniziato	The Benchmark Company	Buy
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-01-05	Iniziato	BMO Capital Markets	Outperform
2021-01-05	Iniziato	Berenberg	Buy
2021-01-05	Iniziato	Credit Suisse	Outperform
2021-01-05	Iniziato	SVB Leerink	Outperform
2021-01-05	Iniziato	Stifel	Buy

Mostra tutto

Abcellera Biologics Inc Borsa (ABCL) Ultime notizie

Nov 20, 2024

ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 19, 2024

GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat

Nov 19, 2024

Nov 13, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 13, 2024

Nov 11, 2024

AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat

Nov 11, 2024

Nov 08, 2024

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 - Business Wire

Nov 07, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St

Nov 07, 2024

Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings - MarketBeat

Nov 07, 2024

AbCellera Unveils Breakthrough T-Cell Platform Data, Shows Promise in Cancer Treatment | ABCL Stock News - StockTitan

Nov 07, 2024

Nov 06, 2024

AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 06, 2024

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at Benchmark - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Given "Buy" Rating at Stifel Nicolaus - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Nov 05, 2024

AbCellera stock price target cut, keeps Outperform on strategic pivot By Investing.com - Investing.com UK

Nov 05, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 05, 2024